Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, ...

Voyager Therapeutics Inc (VYGR) reports robust cash reserves and potential milestone payments, while advancing key gene ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June ...

One year of Tysabri infusion improved working ability for relapsing-remitting multiple sclerosis (RRMS) patients in France, ...

Sangamo Therapeutics, Inc.’s SGMO share price has surged by 10.12%, which has investors questioning if this is right time to ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

That helps explain how a total of 33 stocks in the S&P 500 have implied upside of at least 50% over the next 12 months or so, ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), with a price target ...

Major indices were in the red early on Monday as traders returned from the Easter long-weekend break to escalating tensions ...

IPC Indice de Precios Y Cotizaciones 53,469.19 450.62 0.85% ...

Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...